The Great Rebrander
A report shows that post-M&A rebranding bodes well for the pharmaceutical industry
Maryam Mahdi | | Quick Read
This article was published in our sister publication, The Small Molecule Manufacturer, which celebrates the field of small molecule drug development and manufacturing with interviews and articles focusing on success stories, equipment, and new processing techniques. Read more about The Small Molecule Manufacturer here https://themedicinemaker.com/manufacture/small-but-never-forgotten
According to research published by Brand Finance, pharma is the top-ranked industry when it comes to successful rebranding post-M&A – with average returns of 13.8 percent. But what makes the industry so proficient in managing corporate change? The report, which studied acquisitions worth $500 million or more across 25 sectors, attributes pharma’s success to “superior marketing and client networks of larger players.” The report explains that strategic divestment also prompts companies to rebrand.
Although pharma’s post-takeover rebrands are often successful, they only occur in 31 percent of acquisitions – a figure that may seem small, but still places the medicine making sector ahead of other large industries, including the healthcare (30 percent), telecommunications (29 percent), and oil and gas (25 percent).
Enjoy our FREE content!
Log in or register to gain full unlimited access to all content on the The Medicine Maker site. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.
- Brand Finance, “ Brand Finance Global Rebrand and Architecture Tracker 2020 (GReAT™) report”, (2020). Available at https://bit.ly/2Y1wE8q